ENTITY
Simcere Pharmaceutical Group

Simcere Pharmaceutical Group (2096 HK)

56
Analysis
Health CareChina
Simcere Pharmaceutical Group manufactures and supplies branded generic pharmaceuticals to the China market. The Company's products include antibiotics, anti-cancer medications and anti-stroke medications.
more
bullishRemegen
08 Nov 2020 09:57

A Different Angle - RemeGen Vs Akeso (Insights on Valuation)

In this article, by comparing RemeGen and Akeso's pipelines from different aspects to provide  referable and helpful insights about the valuation...

Logo
352 Views
Share
23 Oct 2020 13:30

Simcere (先声制药) IPO Trading: Mind the Sentiment Changes

We are of the view that the deal will not perform well compared to previous hot biotech deals as it is fairly valued and the sentiment is weak for...

Logo
442 Views
Share
18 Oct 2020 10:51

ECM Weekly (18 October 2020) - Lufax, Simcere, KWG Living, GDS, Jacobio

Aequitas Research puts out a weekly update on the deals that have been covered by the team recently along with updates for upcoming IPOs. This week...

Share
14 Oct 2020 16:08

Simcere Pharmaceutical IPO: Valuation Insights

We think that an attractive PEG valuation and solid cornerstone support makes Simcere tempting at the proposed pricing range

Logo
470 Views
Share
13 Oct 2020 20:39

Simcere (先声制药) IPO: Fairly Valued for a Generic Player

We think the company is fairly valued but will participate in the deal given the likely strong sentiment as the deal is backed by decent...

Logo
331 Views
Share
x